NZ601255A - Anaesthetic formulation - Google Patents
Anaesthetic formulationInfo
- Publication number
- NZ601255A NZ601255A NZ601255A NZ60125511A NZ601255A NZ 601255 A NZ601255 A NZ 601255A NZ 601255 A NZ601255 A NZ 601255A NZ 60125511 A NZ60125511 A NZ 60125511A NZ 601255 A NZ601255 A NZ 601255A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cyclodextrin
- anaesthetic
- neuroactive steroid
- alphadolone
- derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Nanotechnology (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Anesthesiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29724910P | 2010-01-21 | 2010-01-21 | |
| US38531810P | 2010-09-22 | 2010-09-22 | |
| PCT/AU2011/000050 WO2011088503A1 (en) | 2010-01-21 | 2011-01-19 | Anaesthetic formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ601255A true NZ601255A (en) | 2013-09-27 |
Family
ID=44306295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ601255A NZ601255A (en) | 2010-01-21 | 2011-01-19 | Anaesthetic formulation |
Country Status (27)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2631233C (en) | 2005-11-28 | 2011-11-08 | Marinus Pharmaceuticals | Ganaxolone formulations and methods for the making and use thereof |
| US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| SG10201506273PA (en) * | 2011-11-29 | 2015-09-29 | Jurox Pty Ltd | Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug |
| PL2806877T3 (pl) * | 2012-01-23 | 2020-06-01 | Sage Therapeutics, Inc. | Formulacje neuroaktywnego steroidu zawierające kompleks allopregnanolonu i eteru sulfobutylowego beta-cyklodekstryny |
| US20140050789A1 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| RS62761B1 (sr) * | 2012-08-21 | 2022-01-31 | Sage Therapeutics Inc | Alopregnanolon za lečenje refraktornog epileptičkog statusa |
| US9757391B2 (en) | 2012-11-09 | 2017-09-12 | Goodchild Investments Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| DK2925327T3 (da) * | 2012-11-30 | 2024-03-25 | Univ California | Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression |
| WO2015134670A1 (en) * | 2014-03-05 | 2015-09-11 | Mingbao Zhang | Deuterated ganaxolone derivatives |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| IL252848B2 (en) * | 2015-02-06 | 2024-07-01 | Marinus Pharmaceuticals Inc | Intravenous Genaxolone Formulations and Their Use in the Treatment of Epileptic Seizures and Other Seizure Disorders |
| MA45276A (fr) | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation |
| US9585867B2 (en) | 2015-08-06 | 2017-03-07 | Charles Everett Ankner | Cannabinod formulation for the sedation of a human or animal |
| JP2018530585A (ja) | 2015-10-16 | 2018-10-18 | マリナス ファーマシューティカルズ インコーポレイテッド | ナノ粒子を含む注射可能な神経ステロイド製剤 |
| TW202400182A (zh) | 2016-03-08 | 2024-01-01 | 美商賽吉醫療公司 | 神經活性類固醇，其組合物及用途 |
| BR112019002538A2 (pt) | 2016-08-11 | 2019-05-21 | Ovid Therapeutics Inc. | uso de uma composição farmacêutica compreendendo um modulador alostérico, uso de uma composição farmacêutica compreendendo garboxadol ou um sal farmaceuticamente aceitável do mesmo, e composição farmacêutica para a administração parenteral |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| CN111971238B (zh) | 2018-04-16 | 2022-02-18 | 川崎重工业株式会社 | 带式输送机 |
| US11472833B2 (en) | 2018-07-03 | 2022-10-18 | Drawbridge Pharmaceuticals Pty Ltd | Neuroactive steroids and methods of preparation |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| JP2022514991A (ja) * | 2018-12-10 | 2022-02-16 | ハロー・サイエンス・エル・エル・シー | 安定な麻酔薬製剤および関連する剤形 |
| CA3145923A1 (en) | 2019-08-05 | 2021-02-11 | David Czekai | Ganaxolone for use in treatment of status epilepticus |
| CN119950517A (zh) | 2019-12-06 | 2025-05-09 | 马瑞纳斯制药公司 | 用于治疗结节性硬化症的加奈索酮 |
| US11969434B1 (en) | 2022-08-29 | 2024-04-30 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
| US12186327B2 (en) | 2022-08-29 | 2025-01-07 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE100712T1 (de) * | 1989-05-24 | 1994-02-15 | Innovet Inc | Hypoallergene anaesthesierende/hypnotische steroide arzneizubereitung. |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| WO1993017711A1 (en) | 1992-03-11 | 1993-09-16 | Australian Commercial Research & Development Limited | New cyclodextrins and new formulated drugs |
| US5472954A (en) * | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
| JP4227675B2 (ja) * | 1996-10-25 | 2009-02-18 | 康武 日地 | 神経毒軽減麻酔剤 |
| AUPQ633900A0 (en) * | 2000-03-20 | 2000-04-15 | Jurox Pty Ltd | Anaesthetic composition |
| RU2288921C2 (ru) * | 2000-12-19 | 2006-12-10 | Калифорниа Инститьют оф Текнолоджи | Композиции, содержащие комплексы включения |
| US7034013B2 (en) * | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| JP4334229B2 (ja) * | 2001-03-20 | 2009-09-30 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | プロポフォール及びスルホアルキルエーテルシクロデキストリン含有製剤 |
| IL152575A (en) * | 2002-10-31 | 2008-12-29 | Transpharma Medical Ltd | A skin-to-skin transmission system of water-insoluble drugs |
| CA2631233C (en) * | 2005-11-28 | 2011-11-08 | Marinus Pharmaceuticals | Ganaxolone formulations and methods for the making and use thereof |
-
2011
- 2011-01-19 GB GB1210657.1A patent/GB2491491B/en active Active
- 2011-01-19 DK DK11734245.1T patent/DK2525798T3/da active
- 2011-01-19 SI SI201131342T patent/SI2525798T1/en unknown
- 2011-01-19 NZ NZ601255A patent/NZ601255A/xx not_active IP Right Cessation
- 2011-01-19 NO NO11734245A patent/NO2525798T3/no unknown
- 2011-01-19 CN CN201180013975.2A patent/CN102802635B/zh active Active
- 2011-01-19 RS RS20171135A patent/RS56576B1/sr unknown
- 2011-01-19 KR KR1020127021761A patent/KR101747476B1/ko active Active
- 2011-01-19 HR HRP20171699TT patent/HRP20171699T1/hr unknown
- 2011-01-19 PL PL11734245T patent/PL2525798T3/pl unknown
- 2011-01-19 SG SG2012050159A patent/SG181997A1/en unknown
- 2011-01-19 BR BR112012017800-8A patent/BR112012017800B1/pt active IP Right Grant
- 2011-01-19 US US13/574,201 patent/US8697678B2/en active Active
- 2011-01-19 HU HUE11734245A patent/HUE035441T2/en unknown
- 2011-01-19 JP JP2012549208A patent/JP5930311B2/ja active Active
- 2011-01-19 ES ES11734245.1T patent/ES2646829T3/es active Active
- 2011-01-19 RU RU2012134321/15A patent/RU2574022C2/ru active
- 2011-01-19 EP EP11734245.1A patent/EP2525798B1/en active Active
- 2011-01-19 GB GB1201842.0A patent/GB2484244B/en active Active
- 2011-01-19 AU AU2011207103A patent/AU2011207103B2/en active Active
- 2011-01-19 PT PT117342451T patent/PT2525798T/pt unknown
- 2011-01-19 SM SM20170518T patent/SMT201700518T1/it unknown
- 2011-01-19 WO PCT/AU2011/000050 patent/WO2011088503A1/en not_active Application Discontinuation
- 2011-01-19 CA CA2786762A patent/CA2786762C/en active Active
- 2011-01-19 LT LTEP11734245.1T patent/LT2525798T/lt unknown
-
2012
- 2012-07-18 ZA ZA2012/05370A patent/ZA201205370B/en unknown
- 2012-07-20 CL CL2012002032A patent/CL2012002032A1/es unknown
-
2013
- 2013-11-01 US US14/069,751 patent/US8975245B2/en active Active
-
2017
- 2017-11-07 CY CY20171101164T patent/CY1119947T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ601255A (en) | Anaesthetic formulation | |
| SMT202000008T1 (it) | Formulazione di steroide neuroattivo comprendente un complesso di allopregnanolone e solfobutil eter beta-ciclodestrina | |
| PH12015500105A1 (en) | Lavatory treatment device | |
| UA105671C2 (uk) | Фармацевтична композиція, яка містить похідне хіноліну | |
| PH12016500146A1 (en) | Plant disease control composition and its use | |
| PH12016500148A1 (en) | Plant disease control composition and its use | |
| MX2020001262A (es) | Compuestos de platino a base de lipido y nanoparticulas. | |
| JP2013517299A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| BR112013003216A2 (pt) | composições sintéticas de ácido biliar e métodos | |
| WO2013072768A3 (en) | Synthetic derivatives of mpl and uses thereof | |
| WO2014155019A3 (fr) | Composition alcoolique ou hydro-alcoolique parfumante contenant un ether aliphatique | |
| BR112013009825A2 (pt) | uso de misturas de polímero | |
| IN2012DN02093A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| BR112012020603A2 (pt) | síntese de magnolol e seus compostos análogos. | |
| GB201122235D0 (en) | Composition | |
| BR112016013194A2 (pt) | Composições de higiene oral compreendendo carbonato de cálcio e sílica | |
| CA2800424C (en) | B1,2 cyclic beta glucan compound for use to enhance adaptive immunity by activation of dendritic cells | |
| EA201370060A1 (ru) | КЛАТРАТНЫЕ КОМПЛЕКСЫ β-ЦИКЛОДЕКСТРИНА С 1-{[6-БРОМ-1-МЕТИЛ-5-МЕТОКСИ-2-ФЕНИЛТИОМЕТИЛ-1-Н-ИНДОЛ-3-ИЛ]КАРБОНИЛ}-4-БЕНЗИЛПИПЕРАЗИНОМ, ОБЛАДАЮЩИЕ ПРОТИВОВИРУСНОЙ АКТИВНОСТЬЮ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ | |
| ATE538773T1 (de) | Auf prostaglandin basierende zusammensetzung und verfahren zu ihrer verwendung | |
| WO2014166836A8 (en) | Growth hormone compound formulation | |
| MY184686A (en) | Skin cleanser composition | |
| CY1116477T1 (el) | Μεθοδος εnzυμatiκης συνθεσης toy (7s)-3,4-διμεθοξυδικυκλο[4.2.0] οκτα-1,3,5-τριενo-7-καρβοξυλικου οξεος ή εστερων αυτου και εφαρμογη στην συνθεση της ιβαμπραδινης και των αλατων αυτης | |
| IN2014DN07253A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| IN2015DN02814A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| RU2010130899A (ru) | Способ получения неостигмина метилсульфата и неостигмина йодида |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: DRAWBRIDGE PHARMACEUTICALS PTY LTD, AU Effective date: 20131024 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JAN 2016 BY CPA GLOBAL Effective date: 20141204 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JAN 2017 BY CPA GLOBAL Effective date: 20151204 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JAN 2018 BY CPA GLOBAL Effective date: 20161210 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JAN 2019 BY CPA GLOBAL Effective date: 20171208 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JAN 2020 BY CPA GLOBAL Effective date: 20190215 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JAN 2021 BY CPA GLOBAL Effective date: 20191205 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JAN 2022 BY CPA GLOBAL Effective date: 20201203 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JAN 2023 BY CPA GLOBAL Effective date: 20220607 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JAN 2024 BY AMIT SINGH Effective date: 20230715 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JAN 2025 BY FB RICE PTY LTD Effective date: 20240708 |
|
| LAPS | Patent lapsed |